Merus Raises €31M in Series B Financing
Summary
Merus B.V., a Utrecht, The Netherlands-based biopharmaceutical company focusing on innovative human antibody therapeutics, raised an additional €31m (US$42m) in Series B financing.This brought the total amount raised by the company in the Series B round to €47.6m (US$65m).Bakers included new investor Johnson & Johnson Development Corporation (JJDC) and existing investors Novartis Venture Fund, Pfizer Venture Investments, Bay City Capital, LSP (Life Sciences Partners), and Aglaia Oncology Fund.The company is also developing a broad pipeline of preclinical programs that are available for partnering.FinSMEs 03/10/2013 Related News 29/01/2010: The Netherlands, Merus Closes €21.7M Series B Financing
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected